Alogliptin; Alogliptin placebo; Pioglitazone; Pioglitazone placebo
Проводит Takeda
Страница компанииA Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of the Combination of SYR-322 (SYR110322) and Pioglitazone HCl (ACTOS®), in Subjects With Type 2 Diabetes
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00328627/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 18–80 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 1554 чел. во всех странах исследования.
- Плановая дата окончания (03.2008) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Главное из критериев
- ИнфекцииВИЧ, гепатит B или C упомянуты в критериях невключения
Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 14 · невключение: 14
Критерии включения
- Men or women with a historical diagnosis of type 2 diabetes mellitus who were treated with metformin greater than or equal to 1500 mg alone but were experiencing inadequate glycemic control.
- A stable dose of metformin of greater than or equal to 1500 mg or maximum tolerated dose.
- No treatment with antidiabetic agents other than metformin within the 2 months prior to Screening.
- A body mass index greater than or equal to 23 kg/m\^2 and less than or equal to 45 kg/m\^2.
- Fasting C-peptide greater than or equal to 0.8 ng/mL.
- Regular use of other, non-excluded medications was allowed if a stable dose had been established for at least 4 weeks prior to Screening.
- Systolic blood pressure less than or equal to 160 mmHg and diastolic pressure less than or equal to 100 mmHg.
- Hemoglobin greater than or equal to 12 g/dL for men and greater than or equal to 10 g/dL for women.
- Alanine aminotransferase less than or equal to 2.5 times the upper limit of normal.
- Serum creatinine less than 1.5 mg/dL for men and less than 1.4 mg/dL for women.
- Thyroid-stimulating hormone level less than or equal to the upper limit of the normal range and the subject was clinically euthyroid.
- Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.
- Able and willing to monitor their own blood glucose concentrations with a home glucose monitor.
- No major illness or debility that in the investigator's opinion prohibited the patient from completing the study.
Критерии невключения
- Urine albumin/creatinine ratio greater than 113 mg/mmol at Screening.
- A history of cancer, other than squamous cell or basal cell carcinoma of the skin, that had not been in full remission for at least 5 years prior to Screening.
- A history of laser treatment for proliferative diabetic retinopathy within 6 months prior to Screening.
- A history of treated diabetic gastroparesis.
- New York Heart Association Class III or IV heart failure regardless of therapy.
- History of coronary angioplasty, coronary stent placement, coronary bypass surgery, or myocardial infarction within the 6 months prior to Screening.
- History of any hemoglobinopathy.
- History of infection with hepatitis B, hepatitis C or human immunodeficiency virus.
- History of a psychiatric disorder that could have affected the patient's ability to participate in the study.
- History of angioedema in association with use of angiotensin-converting enzyme inhibitors or angiotensin-II receptor inhibitors.
- A history of alcohol or substance abuse within 2 years prior to Screening.
- Receipt of any investigational drug within 30 days prior to Screening or a history of receipt of an investigational antidiabetic drug within 3 months prior to Screening.
- Previous participation in an investigational study of alogliptin.
- Hypersensitive to pioglitazone, alogliptin, or other excipients.
Источник: ClinicalTrials.gov, NCT00328627 · запись обновлена в реестре 4 апреля 2013.
Дизайн и результаты
Что измеряют — первичные конечные точки (2), вторичных — 154
- Change From Baseline to Week 26 in Glycosylated Hemoglobin (HbA1c) (Grouped Analysis) — Baseline and Week 26
- Change From Baseline to Week 26 in HbA1c — Baseline and Week 26
Цель исследования
The purpose of this study is to evaluate the safety and efficacy of alogliptin, once daily (QD), taken in combination with pioglitazone in adults with type 2 diabetes mellitus.
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00328627 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.